Why this matters — Three distinct ORTEX data types — utilization, cost to borrow, and options — have aligned simultaneously on INFY. The convergence has persisted across multiple days, making this one of the more sustained multi-signal setups in the IT services space.
Utilization at maximum. Utilization for Infosys has sat at 100% since late March. That is a 30-day streak at the 52-week high. Every share available to borrow is already lent out. New short positions cannot be established through normal stock lending.
Cost to borrow exploding. CTB stood at 23.08% APR as of April 24. That is up 55% in one week and 111% over the past month. A month ago CTB was around 11%. The doubling reflects severe supply pressure in the lending market.
Options market stays bearish. The put/call ratio hit 3.45 in the days ahead of the April 23 earnings print. It has since eased to 2.73 but remains above the 20-day mean of 2.19. The 52-week PCR high is 4.14, so the current reading is still elevated by historical standards.
Analysts moved quickly after earnings. BMO Capital lowered its target from $20 to $15 on April 24. Susquehanna cut from $16 to $14 the same day. TD Cowen trimmed to $15 in early April. All three maintained neutral or hold ratings. The mean analyst target now sits at $14.68, versus a closing price of $12.86 — a modest implied upside, but one built on recently-reduced estimates. The ORTEX short score reached 73.2 on April 23, up from 70.2 two weeks prior. The EPS momentum 30-day factor ranks at the 86th percentile, a notable divergence from the bearish short-side setup.
Utilization has been at or near 100% for most of the past 30 days, with only a brief dip to 95.3% on March 24. This is not a spike — it is a structural condition. CTB was already above 10% through March. The current 23% level represents a step-change acceleration, not simply a continuation of the existing trend.
See the live data behind this article on ORTEX.
Open INFY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
